Sign Up for a Free Account
  • Updated 04.23.2021
  • Released 05.15.2017
  • Expires For CME 04.23.2024



Historical note and terminology

Edaravone, a free radical scavenger, was approved in Japan for the treatment of cerebral infarction in 2005 and was available in South Korea as well. It was approved for the treatment of amyotrophic lateral sclerosis in those countries in 2015. Edaravone was approved by the U.S. Food and Drug Administration (FDA) in 2017 and is available in the United States. This is the first approval of a new drug for amyotrophic lateral sclerosis since the approval of the only other drug for amyotrophic lateral sclerosis, riluzole, more than 2 decades ago (14). The drug will be sold under the brand name Radicava, and 1 year of treatment costs more than $145,000. The manufacturer will provide some copay assistance to patients with commercial insurance and other help to those who are uninsured or face delays in coverage. Those who qualify might even be treated for free.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125